
THERANOSTICS CONSULTING provides R&D, Medical and Strategic Consulting Services to Pharma, Biotech, and Investment companies.

It is a new concept that combines the use of specific targeted diagnostic tests and therapies applied on the same specific targets.
A recent example is the concomitant development and commercialization of theranostics radiopharmaceutical pairs for the treatment of gastro-entero-pancreatic neuroendocrine tumors:
68Ga-dotatate is a radiopharmaceutical imaging agent used for the diagnostic of gastro-entero-pancreatic neuroendocrine tumors.
It is formed of 68Ga, an isotope of Gallium emitting gamma radiations for use in PET-CT scanning and octreotide, a peptide specifically targeting type 2-somatostatin receptors that are overexpressed in gastro-enter-pancreatic neuroendocrine cancers.
At the same time, a therapeutic pair to treat gastro-entero-pancreatic neuroendocrine tumors was developed to form 177Lu-dotatate by only substituting 68Ga by 177Lu (an isotope of Lutetium emitting beta radiations for cancer therapy), but keeping the same peptide, octreotide.
Theranostics, by combining diagnostics and therapy, brings new opportunities for personalized medicine by delivering patients the right treatment at the right time.
of development for small to large pharmaceutical and biotech companies, as well for investment firms. However, because it is a very complex and emerging area, expertise is needed to guide strategic decisions and avoid taking wrong pathways. Theranostics Consulting experts combine decades of practice and expertise in diagnostic field (radiopharmaceuticals and
contrast agents) and in development of therapeutic drugs (in oncology, immuno-oncology, cardiology and neurology). Theranostics Consulting is able to assist
you in taking the right decision in this complex area by providing global expertise in US, Europe and emerging markets.

Theranostics Consulting will assist you in the following areas:
Contact us at: contact@theranostics.fr